As nicotine pouches continue to attract regulatory attention, a recurring challenge for policymakers is separating assumptions from evidence. Much of the debate has focused on hypothetical risks, youth narratives, or product novelty, while comparatively less attention has been paid to how adult users actually perceive and use these products in real-world contexts. A recent peer-reviewed…
Following GINN’s recent market‑insights visit to Lebanon, led by our Director Shem Baldeosingh, we continue to learn from frontline experts who see the realities of nicotine use, smoking, and harm reduction every day. This week, Dr Vera Matta (@dr.veramatta), a respected clinician and public health communicator, highlighted an important point while reviewing REBEL White Slim…
As nicotine pouches continue to expand across multiple markets, questions about who uses them, why they are used, and how they fit into tobacco control strategies are becoming increasingly important. A recent peer-reviewed article published by Springer adds to this evidence base by examining patterns of nicotine pouch use and their implications for public health…
As regulators continue to assess the role of nicotine pouches within tobacco control frameworks, evidence on how these products are actually used over time remains limited. A recently published prospective study in Cureus helps address this gap by examining real-world patterns of nicotine pouch use across a ten-week period. The study is important not because…
Executive context Innovation in nicotine pouches has largely focused on formulation variables, nicotine strength, pH, buffering systems, flavours, and moisture content. These factors shape nicotine delivery and user perception and are central to regulatory assessment. However, a growing body of clinical, observational, and design-science evidence indicates that oral tolerability and mucosal outcomes are also strongly…
Regulation, clinical context, and evidence-based harm reduction Cigarette smoking continues to impose a disproportionate health burden in Appalachia, a region marked by persistently high smoking prevalence, elevated rates of cardiovascular disease and cancer, and long-standing socioeconomic barriers to cessation support. Despite decades of tobacco control efforts, combustible cigarette use remains entrenched in many Appalachian communities,…
Nicotine pouch performance is often discussed almost exclusively in terms of formulation. Nicotine concentration, pH, buffering systems, flavour chemistry, and moisture balance dominate both technical development and regulatory review. These elements are undeniably important. However, emerging evidence and user experience suggest that formulation alone does not fully explain how nicotine pouches are tolerated, used, or…
Youth “addiction” to nicotine pouches and other smoke-free nicotine products is increasingly invoked as a political shorthand, often without reference to how addiction is actually defined in modern clinical science. This matters, because the DSM-5 framework, the global reference standard for diagnosing substance-related disorders, does not define addiction by frequency of use alone, nor does…
As nicotine pouches gain visibility in the United States and other markets, debate around their public-health role has intensified. Much of this discussion has been driven by concern over youth uptake and regulatory uncertainty. However, recent reporting in JAMA highlights a more nuanced picture, one in which several public-health experts recognise that nicotine pouches differ…
As nicotine pouch use expands globally, regulatory debate is increasingly framed as a choice between bans and permissive access. That framing is misleading. Evidence now points toward a more effective third path: risk-proportionate regulation that shapes product design to reduce harm while preserving adult access. Nicotine pouches are neither risk-free nor uniform. Their public-health impact…